English | Español

Janssen Biotech, Inc.
Nicholas Gueguen | Aug 17, 2017

FDA gives Imbruvica go-ahead to aid patients with chronic graft versus host disease
Jamie Barrand | Mar 9, 2016

FDA approves Imbruvica as first-line therapy for chronic lymphocytic leukemia
Jamie Barrand | Sep 17, 2015

Janssen's multiple myeloma drug accepted for FDA priority review

Trending
Patient Daily | Aug 18, 2025

Medfluence Advisors’ Greg Caesar to open ASCENT 2025 with keynote on digital practice growth
+ Pharmaceuticals
Patient Daily | Aug 18, 2025

Patients Come First spokesperson on 340B rebate model: ‘This rebate model provides the oversight that 340B has needed for decades’
Patient Daily | Aug 21, 2025

SoCal Breathe Free doctor on balloon sinuplasty: ‘The procedure itself is pretty quick and effectiveness is pretty high’
+ Pharmaceuticals
Patient Daily | Aug 21, 2025

PhRMA director of public affairs on 340B rebate model: "Positive first step toward addressing hospital abuse of the 340B program